2 results match your criteria: "Poland ‡Geisinger Medical Center Clinic[Affiliation]"
Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD.
J Pediatr Gastroenterol Nutr
April 2014
*Pediatric & Adolescent Gastroenterology & Nutrition, Youngstown, OH †Children's Memorial Health Institute, Warsaw, Poland ‡Geisinger Medical Center Clinic, Wilkes-Barre, PA §Gastrointestinal Associates, Jackson, MS ||Janssen Research & Development, LLC, Raritan, NJ.
Objective: The aim of the present study was to evaluate 24-week maintenance of efficacy and safety of rabeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD).
Methods: Children ages 1 to 11 years who achieved endoscopic/histologic healing (defined as grade 0 of the Hetzel-Dent Classification scale and/or grade 0 of the Histological Features of Reflux Esophagitis scale) in a 12-week treatment phase were continued on the same dose for an additional 24 weeks during the maintenance phase. The dose was determined by weight: children weighing 6 to 14.
Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
J Pediatr Gastroenterol Nutr
December 2013
*Pediatric & Adolescent Gastroenterology & Nutrition, Youngstown, OH †Children's Memorial Health Institute, Warsaw, Poland ‡Geisinger Medical Center Clinic, Wilkes Barre, PA §Gastrointestinal Associates, Jackson, MS ||Janssen Research & Development, LLC, Titusville, NJ.
Objective: Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD).
Methods: Children were randomized to 0.5- or 1.